Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBIAT (2020 - 2023)

Historic EBIAT for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.1 million.

  • Immuneering's EBIAT fell 1387.58% to -$15.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$53.5 million, marking a year-over-year decrease of 585.6%. This contributed to the annual value of -$53.5 million for FY2023, which is 585.6% down from last year.
  • As of Q4 2023, Immuneering's EBIAT stood at -$15.1 million, which was down 1387.58% from -$12.6 million recorded in Q3 2023.
  • In the past 5 years, Immuneering's EBIAT registered a high of -$3.6 million during Q2 2020, and its lowest value of -$15.1 million during Q4 2023.
  • For the 4-year period, Immuneering's EBIAT averaged around -$10.1 million, with its median value being -$11.5 million (2022).
  • As far as peak fluctuations go, Immuneering's EBIAT tumbled by 12162.34% in 2021, and later skyrocketed by 193.95% in 2023.
  • Immuneering's EBIAT (Quarter) stood at -$5.8 million in 2020, then crashed by 84.79% to -$10.8 million in 2021, then decreased by 22.82% to -$13.2 million in 2022, then fell by 13.88% to -$15.1 million in 2023.
  • Its EBIAT was -$15.1 million in Q4 2023, compared to -$12.6 million in Q3 2023 and -$12.2 million in Q2 2023.